IP Library › Assignment 074408/0883
Patent Assignment
Reel/Frame 074408/0883

Assignment of Assignor's Interest

Recorded: 2026-04-19 Pages: 6
Assignor
SETH, SANDESH
Executed: 2026-03-30
Assignee
ACTINIUM PHARMACEUTICALS, INC.
100 PARK AVENUE, 23RD FLOOR, NEW YORK, NEW YORK, 10017
Covered Properties (21)
Radioimmunoconjugates Targeting Calreticulin for Use in the Treatment of Cancer
Application: 63/233,577 →
Radioimmunoconjugates Targeting Calreticulin for Use in the Treatment of Cancer
Application: 18/684,103 →
Publication: US 2024/0226345
Radioimmunoconjugates Targeting Phosphatidylserine for Use in the Treatment of Cancer
Application: 18/685,667 →
Publication: US 2025/0339571
Radioimmunoconjugates Targeting GRP78 for Use in the Treatment of Cancer
Application: 18/696,453 →
Publication: US 2024/0390532
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 63/116,225 →
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 17/532,919 →
Publication: US 2022/0143228
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 18/146,149 →
Publication: US 2023/0248855
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Application: 18/392,556 →
Publication: US 2025/0205375
Methods for Treating CD33-Positive Hematological Malignancies
Application: 63/298,532 →
Methods for Treating CD33-Positive Hematological Malignancies
Application: 18/728,076 →
Publication: US 2025/0073274
Radioimmunoconjugates Directed to CCR8 for Depletion of Tumor Infiltrating Regulatory T Cells
Application: 63/171,790 →
Radioimmunotherapy Directed to CCR8 for Depletion of Tumor Infiltrating Regulatory T Cells
Application: 18/553,757 →
Publication: US 2024/0197931
Radioimmunoconjugates Directed to NKG2D Ligands for the Treatment of Cancer
Application: 18/557,988 →
Publication: US 2024/0216554
Radioimmunoconjugates Targeting Calreticulin for Use in the Treatment of Cancer
Radioimmunoconjugates Targeting Phosphatidylserine for Use in the Treatment of Cancer
Radioconjugates Targeting GRP78 for Use in the Treatment of Cancer
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
Methods for Treating CD33-Positive Hematological Malignancies
Radioimmunotherapy Directed to CCR8 for Depletion of Tumor Infiltrating Regulatory T Cells
Radioimmunoconjugates Directed to NKG2D Ligands for the Treatment of Cancer
Related Assignments (5)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Nov 20, 2020
From: LUDWIG, DALE L; GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 054427/0633 →
Assignment of Assignor's Interest Apr 7, 2021
From: GEOGHEGAN, EILEEN; LUDWIG, DALE L; SETH, SANDESH; HWANG, JESSE
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 055854/0296 →
Assignment of Assignor's Interest Apr 20, 2026
From: LUDWIG, DALE L.
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 074408/0977 →
Assignment of Assignor's Interest Jul 28, 2026
From: GEOGHEGAN, EILEEN
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 075413/0363 →
Assignment of Assignor's Interest Jul 28, 2026
From: DIAMOND, PAUL
To: ACTINIUM PHARMACEUTICALS, INC.
Reel/Frame 075413/0388 →